Tumor Biology

, Volume 35, Issue 3, pp 2817–2824

High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast

  • Abdelbaset Buhmeida
  • Ashraf Dallol
  • Adnan Merdad
  • Jaudah Al-Maghrabi
  • Mamdooh A. Gari
  • Muhammad M. Abu-Elmagd
  • Adeel G. Chaudhary
  • Adel M. Abuzenadah
  • Taoufik Nedjadi
  • Eramah Ermiah
  • Fatima Al-Thubaity
  • Mohammed H. Al-Qahtani
Research Article

DOI: 10.1007/s13277-013-1374-y

Cite this article as:
Buhmeida, A., Dallol, A., Merdad, A. et al. Tumor Biol. (2014) 35: 2817. doi:10.1007/s13277-013-1374-y

Abstract

Metabolic diseases like diabetes and obesity are major risk factors for breast cancer. Aberrant expression of metabolic effectors such as fibroblast growth factor 19 (FGF19) could be therefore associated with the disease. The expression of FGF19 was examined in 193 archival breast tumor samples by immunohistochemistry and evaluated semi-quantitatively by determining the staining index and correlating it with clinicopathological parameters using Fisher's exact test. The correlation between FGF19 expression and 5-year disease-specific survival rate was determined using the univariate Kaplan–Meier analysis. The prognostic value of FGF19 expression was evaluated using the multivariate Cox regression analysis. Of the 193 tumors analyzed, 40 % were classified with low FGF19 expression, whereas 60 % were categorized as tumors with high FGF19 expression. There was a highly significant correlation between high FGF19 expression and patients' age (p = 0.008) as well as 5-year disease-specific survival (p = 0.001). However, FGF19 expression did not show any significant correlations with other clinicopathological parameters, including hormonal status, tumor grade, tumor size, or lymph node status. Univariate Kaplan–Meier log rank analysis showed that patients with high FGF19 expression exhibited a significantly shorter disease-specific 5-year survival (p = 0.007). This effect was exacerbated by lymph node metastasis (p = 0.001), negative estrogen receptor (ER) status (p = 0.002), or old age (p = 0.013). Multivariate analysis showed that high FGF19 expression could be an independent prognostic marker of disease-specific survival in breast cancer patients (p = 0.030). Quantification of FGF19 expression appears to provide valuable prognostic information in breast cancer, particularly in older patients with lymph node metastasis and negative ER status.

Keywords

FGF19 expression Breast cancer Lymph node positive IHC Prognosis Targeted therapy 

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Abdelbaset Buhmeida
    • 1
  • Ashraf Dallol
    • 1
    • 2
  • Adnan Merdad
    • 3
  • Jaudah Al-Maghrabi
    • 4
  • Mamdooh A. Gari
    • 1
    • 5
  • Muhammad M. Abu-Elmagd
    • 1
    • 8
  • Adeel G. Chaudhary
    • 1
    • 5
  • Adel M. Abuzenadah
    • 1
    • 2
    • 5
  • Taoufik Nedjadi
    • 6
  • Eramah Ermiah
    • 7
  • Fatima Al-Thubaity
    • 3
  • Mohammed H. Al-Qahtani
    • 1
    • 5
  1. 1.Center of Excellence in Genomic Medicine ResearchKing Abdulaziz UniversityJeddahKingdom of Saudi Arabia
  2. 2.KACST Technology Innovation Center in Personalized MedicineKing Abdulaziz UniversityJeddahKingdom of Saudi Arabia
  3. 3.Department of Surgery, Faculty of MedicineKing Abdulaziz UniversityJeddahKingdom of Saudi Arabia
  4. 4.Department of Pathology, Faculty of MedicineKing Abdulaziz UniversityJeddahKingdom of Saudi Arabia
  5. 5.Faculty of Applied Medical SciencesKing Abdulaziz UniversityJeddahKingdom of Saudi Arabia
  6. 6.King Fahd Medical Research CenterKing Abdulaziz UniversityJeddahKingdom of Saudi Arabia
  7. 7.Department of OncologyNational Cancer InstituteSabrathaLibya
  8. 8.Zoology Department, Faculty of ScienceMinia UniversityMiniaEgypt

Personalised recommendations